.

The changing landscape in the treatment of metastatic castration-resistant prostate cancer

LAUR Repository

Show simple item record

dc.contributor.author El Amm, Joelle
dc.contributor.author Aragon-Ching, Jeanny B.
dc.date.accessioned 2017-09-22T11:16:48Z
dc.date.available 2017-09-22T11:16:48Z
dc.date.copyright 2012 en_US
dc.date.issued 2017-09-22
dc.identifier.issn 1758-8359 en_US
dc.identifier.uri http://hdl.handle.net/10725/6239
dc.description.abstract The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking. en_US
dc.language.iso en en_US
dc.title The changing landscape in the treatment of metastatic castration-resistant prostate cancer en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201603787 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Therapeutic Advances in Medical Oncology en_US
dc.journal.volume 5 en_US
dc.journal.issue 1 en_US
dc.article.pages 25-40 en_US
dc.keywords Androgen deprivation therapy en_US
dc.keywords Chemotherapy en_US
dc.keywords Metastatic castration-resistant prostate cancer en_US
dc.keywords Vaccine therapy en_US
dc.identifier.doi http://dx.doi.org/ 10.1177/ 1758834012458137 en_US
dc.identifier.ctation El-Amm, J., & Aragon-Ching, J. B. (2013). The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Therapeutic advances in medical oncology, 5(1), 25-40. en_US
dc.author.email joelle.elamm@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://journals.sagepub.com/doi/abs/10.1177/1758834012458137 en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account